CD38 and central nervous system cancer: The current study revealed that a subset of effector CD8+ T cells characterized as CD38+HLA-DR+CD8+ existed in both the peripheral blood and the tumor microenvironment, which indicated that the immune system of patients with glioma could recognize the tumor cells at an early stage.